The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ICPT, HPQ and BSX
Back to Newsroom
Mentioned in this Article

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ICPT, HPQ and BSX

Tuesday, December 22, 2020 12:00 PM
Share this article now
Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / December 22, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

Investors Affected : September 28, 2019 - October 7, 2020

A class action has commenced on behalf of certain shareholders in Intercept Pharmaceuticals, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Defendants downplayed the true scope and severity of safety concerns associated with the use of Ocaliva (obeticholic acid ("OCA")), Intercept's lead product candidate, in treating primary biliary cholangitis; (ii) the foregoing increased the likelihood of a U.S. Food and Drug Administration ("FDA") investigation into Ocaliva's development, thereby jeopardizing Ocaliva's continued marketability and the sustainability of its sales; (iii) any purported benefits associated with OCA's efficacy in treating nonalcoholic steatohepatitis ("NASH") were outweighed by the risks of its use; (iv) as a result, the FDA was unlikely to approve the Company's New Drug Application for OCA in treating patients with liver fibrosis due to NASH; and (v) as a result of all the foregoing, the Company's public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/intercept-pharmaceuticals-inc-loss-submission-form/?id=11748&from=1

HP Inc. (NYSE:HPQ)

Investors Affected : November 6, 2015 - June 21, 2016

A class action has commenced on behalf of certain shareholders in HP Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) HP's channel inventory management and sales practices resulted in the sale of supplies to customers that did not need or want the product in order to artificially increase revenues and profits; (b) HP's channel inventory management and sales practices resulted in the sale of supplies to customers outside of designated regions at unsustainable discounts in order to artificially increase revenues and profits; (c) HP's channel inventory management and sales practices resulted in the sale of supplies at steep discounts to customers to encourage those customers to sell the supplies further down the supply channel, out of HP's inventory management metrics; and (d) as a result of (a)-(c) above, defendants' statements about HP's business condition and prospects were materially false and misleading when made.

Shareholders may find more information at https://securitiesclasslaw.com/securities/hp-inc-loss-submission-form-2/?id=11748&from=1

Boston Scientific Corporation (NYSE:BSX)

Investors Affected : April 24, 2019 - November 16, 2020

A class action has commenced on behalf of certain shareholders in Boston Scientific Corporation. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the LOTUS Edge Aortic Valve System's product delivery system was dysfunctional and threatened the continued viability of the entire product line; (ii) as a result, the Company had materially overstated the continued commercial viability and profitability of the LOTUS Edge Aortic Valve System; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/boston-scientific-corporation-loss-submission-form/?id=11748&from=1

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (212) 537-9430
Fax: (833) 862-7770

SOURCE: The Gross Law Firm

The Gross Law Firm
Back to Newsroom
Copyright 2021 © ACCESSWIRE. All rights reserved. Privacy Policy  |   Terms and Conditions